Previous Close | 3.0000 |
Open | 3.0200 |
Bid | 3.0100 x 1400 |
Ask | 3.4200 x 4000 |
Day's Range | 2.9750 - 3.2150 |
52 Week Range | 2.9050 - 25.0550 |
Volume | |
Avg. Volume | 767,130 |
Market Cap | 295.196M |
Beta (5Y Monthly) | 3.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9440 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.38 |
Subscribe to Yahoo Finance Plus to view Fair Value for MCRB
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinic
CAMBRIDGE, Mass., May 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle. These data were shared in oral and poster presentations at t
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f